Se Hyun Kim

Se Hyun Kim

Auto-generated profile, based on publicly available information

Se Hyun Kim

Department of Psychiatry, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
JLJose de Leon
Jose de Leon
GSGeorgios Schoretsanitis
Georgios Schoretsanitis
RSRobert L. Smith
Robert L. Smith
EMEspen Molden
Espen Molden
ASAnssi Solismaa
Anssi Solismaa
DMDaniel Mueller
Daniel Mueller
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.

3 April 2020 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
SRSang Jin Rhee
Sang Jin Rhee
DHDohyun Han
Dohyun Han
YLYunna Lee
Yunna Lee
HKHyeyoung Kim
Hyeyoung Kim
JLJunhee Lee
Junhee Lee
KHKyooseob Ha
Kyooseob Ha
Background: Major depressive disorder and bipolar disorder are prevalent and debilitating psychiatric disorders that are difficult to distinguish, as their diagnosis is based on behavioural observations and subjective symptoms. Quantitative protein profile analysis might help to objectively distinguish between these disorders and increase our understanding of their pathophysiology. Thus, this study was conducted to compare the peripheral protein profiles between the two disorders. Methods: Serum samples were collected from 18 subjects with major depressive disorder and 15 subjects with bipolar disorder. After depleting abundant proteins, liquid chromatography-tandem mass spectrometry (LC-MS/MS) and label-free quantification were performed. Data-dependent acquisition data were statistically analysed from the samples of 15 subjects with major depressive disorder and 10 subjects with bipolar disorder who were psychotropic drug-free. Two-sided t-tests were performed for pairwise comparisons of proteomes to detect differentially-expressed proteins (DEPs). Ingenuity Pathway Analysis of canonical pathways, disease and functions, and protein networks based on these DEPs was further conducted. Results: Fourteen DEPs were significant between subjects with major depressive disorder and those with bipolar disorder. Ras-related protein Rab-7a (t = 5.975, p = 4.3 × 10− 6) and Rho-associated protein kinase 2 (t = 4.782, p = 8.0 × 10− 5) were significantly overexpressed in subjects with major depressive disorder and Exportin-7 (t = -4.520, p = 1.5 × 10− 4) was significantly overexpressed in subjects with bipolar disorder after considering multiple comparisons. Bioinformatics analysis showed that cellular functions and inflammation/immune pathways were significantly different. Conclusions: Ras-related protein Rab-7a, Rho-associated protein kinase 2, and Exportin-7 were identified as potential peripheral protein candidates to distinguish major depressive disorder and bipolar disorder. Further large sample studies with longitudinal designs and validation processes are warranted.

10 March 2014 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
HPHong Geun Park
Hong Geun Park
HYHyun Sook Yu
Hyun Sook Yu
SPSoyoung Park
Soyoung Park
YAYong Min Ahn
Yong Min Ahn
YKYong Sik Kim
Yong Sik Kim
SKSe Hyun Kim
Se Hyun Kim
The enzymatic activity of histone deacetylases (HDACs) leads to a histone deacetylation-mediated condensed chromatic structure, resulting in transcrip

1 May 2017 in Comprehensive Psychiatry
Verified
Journal Article
Closed access
HPHyung Keun Park
Hyung Keun Park
SYSeong Ho Yoo
Seong Ho Yoo
JLJaewon Lee
Jaewon Lee
SCSung Joon Cho
Sung Joon Cho
MSMin-Sup Shin
Min-Sup Shin
YAYong Min Ahn
Yong Min Ahn

1 May 2023 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
JLJose de Leon
Jose de Leon
MRManuel Arrojo Romero
Manuel Arrojo Romero
HVHélène Verdoux
Hélène Verdoux
CRCan-Jun Ruan
Can-Jun Ruan
GSGeorgios Schoretsanitis
Georgios Schoretsanitis
Carlos De Las CuevasCarlos De Las Cuevas
Carlos De Las Cuevas
Purpose/Background: A recent article in this journal presented a US perspective regarding the modernization of clozapine prescription and proposed an escape from the long shadow cast by agranulocytosis. Methods: Here, an international group of collaborators discusses a point of view complementary to the US view by focusing on worldwide outcomes of clozapine usage that may be uneven in terms of frequency of clozapine adverse drug reactions. Findings/Results: Studies from the Scandinavian national registries (Finland and Denmark) did not find increased mortality in clozapine patients or any clear evidence of the alleged toxicity of clozapine. Data on clozapine-associated fatal outcomes were obtained from 2 recently published pharmacovigilance studies and from the UK pharmacovigilance database. A pharmacovigilance study focused on physician reports to assess worldwide lethality of drugs from 2010 to 2019 found 968 clozapine-associated fatal outcomes in the United Kingdom. Moreover, the United Kingdom accounted for 55% (968 of 1761) of worldwide and 90% (968 of 1073) of European fatal clozapine-associated outcomes. In a pharmacovigilance study from the UK database (from 2008 to 2017), clozapine was associated with 383 fatal outcomes/year including all reports from physicians and nonphysicians. From 2018 to 2021, UK clozapine-associated fatal outcomes increased to 440/year. Implications/Conclusions: The interpretation of fatal outcomes in each country using pharmacovigilance databases is limited and only allows gross comparisons; even with those limitations, the UK data seem concerning. Pneumonia and myocarditis may be more important than agranulocytosis in explaining the uneven distribution of fatal outcomes in clozapine patients across countries.

26 September 2023 in Schizophrenia Research
Verified
Journal Article
Closed access
NKNuree Kang
Nuree Kang
SKSe Hyun Kim
Se Hyun Kim
JKJayoun Kim
Jayoun Kim
SKSungkyu Kim
Sungkyu Kim
JJJinhyeok Jang
Jinhyeok Jang
JKJun Soo Kwon
Jun Soo Kwon